NIR-II nanoprobes in-vivo assembly to improve image-guided surgery for metastatic ovarian cancer

Nat Commun. 2018 Jul 24;9(1):2898. doi: 10.1038/s41467-018-05113-8.

Abstract

Local recurrence is a common cause of treatment failure for patients with solid tumors. Tumor-specific intraoperative fluorescence imaging may improve staging and debulking efforts in cytoreductive surgery and, thereby improve prognosis. Here, we report in vivo assembly of the second near-infrared window (NIR-II) emitting downconversion nanoparticles (DCNPs) modified with DNA and targeting peptides to improve the image-guided surgery for metastatic ovarian cancer. The NIR-II imaging quality with DCNPs is superior to that of clinically approved ICG with good photostability and deep tissue penetration (8 mm). Stable tumor retention period experienced 6 h by in vivo assembly of nanoprobes can be used for precise tumor resection. Superior tumor-to-normal tissue ratio is successfully achieved to facilitate the abdominal ovarian metastases surgical delineation. Metastases with ≤1 mm can be completely excised under NIR-II bioimaging guidance. This novel technology provides a general new basis for the future design of nanomaterials for medical applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Female
  • Humans
  • Mice
  • Microscopy, Electron, Transmission
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Neoplasm Metastasis
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery*
  • Prognosis
  • Reproducibility of Results
  • Spectroscopy, Near-Infrared / methods*
  • Surgery, Computer-Assisted / methods*
  • Xenograft Model Antitumor Assays*